                         SEQUENCE LISTING

<110>  University of Zurich
       Nitsch, Roger
       Lindvalle, Olle
       Biscaro, Barbara
       Ekdahl, Christine
 
<120>  Method of Promoting Neurogenesis

<130>  2159.218PC01

<150>  US 61/079,379
<151>  2008-07-09

<160>  54    

<170>  PatentIn version 3.3

<210>  1
<211>  372
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.11

<400>  1
gaggtgcagc tggtgcagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60

tcctgtgcag cgtctggatt cgccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatggtttg atggaactaa aaaatactat    180

acagactccg tgaagggcag attcaccatc tccagagaca attccaagaa cacactgtat    240

ctgcaaatga acaccctgag agccgaggac acggctgtgt attactgtgc gagagatagg    300

ggtataggag ctcggcgggg gccgtactac atggacgtct ggggcaaagg gaccacggtc    360

accgtctcct ca                                                        372


<210>  2
<211>  327
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13B

<400>  2
gacatccagt tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc     60

atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagattcca    120

gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca    180

aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct    240

gatgattttg caacttatta ctgccaacag tataatagtt attctcgaac gttcggccaa    300

gggaccaagc tggagatcaa acgtacg                                        327


<210>  3
<211>  372
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.10

<400>  3
gaggtgcagc tagtgcagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60

tcctgtgcag cgtctggatt cgccttcagt agctatggca tacactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatggtttg atggaactaa aaaatactat    180

acagactccg tgaagggcag attcaccatc tccagagaca attccaagaa cacactgtat    240

ctgcaaatga acaccctgag agccgaggac acggctgtgt attactgtgc gagagatagg    300

ggtataggag ctcggcgggg gccgtactac atggacgtct ggggcaaagg gaccacggtc    360

accgtctcct ca                                                        372


<210>  4
<211>  124
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.10

<400>  4

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr 
            20                  25                  30          


Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Phe Asp Gly Thr Lys Lys Tyr Tyr Thr Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Gly Ile Gly Ala Arg Arg Gly Pro Tyr Tyr Met Asp 
            100                 105                 110         


Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 


<210>  5
<211>  372
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.11

<400>  5
gaggtgcagc tggtgcagag cggcggcggc gtggtgcagc ccggccggag cctgcggctg     60

agctgcgccg ccagcggctt cgccttcagc agctacggca tgcactgggt gcggcaggcc    120

cccggcaagg gcctggagtg ggtggccgtg atctggttcg acggcaccaa gaagtactac    180

accgacagcg tgaagggccg gttcaccatc agccgggaca acagcaagaa caccctgtac    240

ctgcagatga acaccctgcg ggccgaggac accgccgtgt actactgcgc ccgggaccgg    300

ggcatcggcg cccggcgggg cccctactac atggacgtgt ggggcaaggg caccaccgtg    360

accgtgagca gc                                                        372


<210>  6
<211>  124
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.11

<400>  6

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Phe Asp Gly Thr Lys Lys Tyr Tyr Thr Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Gly Ile Gly Ala Arg Arg Gly Pro Tyr Tyr Met Asp 
            100                 105                 110         


Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 


<210>  7
<211>  327
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.10 and NI-101.11

<400>  7
gaaattgtgc tgactcagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc     60

atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca acagaaacca    120

gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca    180

aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct    240

gaagattttg caacttatta ctgtcagcag agttacagta cccctctcac tttcggcgga    300

gggaccaagc tcgagatcaa acgtacg                                        327


<210>  8
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.10 and NI-101.11

<400>  8

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105             


<210>  9
<211>  381
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.12

<400>  9
gaggtgcagc tggtggagag cggccccggc ctggtgaagc ccgccgagac cctgagcctg     60

acctgcaccg tgagcggcgg cagcatccgg agcggcagca tctgctggta ctggatccgg    120

cagccccccg gcaagggcct ggagtggatc ggctacttct gctacagcgg cgccaccttc    180

tacaccccca gcctgcgggg ccggctgacc atcagcgtgg acgccagcaa gaaccagctg    240

agcctgagcc tgagcagcgt gaccgccgcc gacaccgccg tgtactactg cgcccggcgg    300

gccggcgaga acagcggcgg catcgagccc tactacggca tggacgtgtg gggccagggc    360

accaccgtga ccgtgagcag c                                              381


<210>  10
<211>  127
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.12

<400>  10

Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ala Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Arg Ser Gly 
            20                  25                  30          


Ser Ile Cys Trp Tyr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ile Gly Tyr Phe Cys Tyr Ser Gly Ala Thr Phe Tyr Thr Pro Ser 
    50                  55                  60                  


Leu Arg Gly Arg Leu Thr Ile Ser Val Asp Ala Ser Lys Asn Gln Leu 
65                  70                  75                  80  


Ser Leu Ser Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Arg Ala Gly Glu Asn Ser Gly Gly Ile Glu Pro Tyr Tyr 
            100                 105                 110         


Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 125         


<210>  11
<211>  330
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.12

<400>  11
gacgagatcg tgctgaccca gagccccagc agcctgagcg ccagcatcgg cgaccgggtg     60

accatcacct gccgggccag cgagagcatc aacaagtacg tgaactggta ccagcagaag    120

cccggcaagg cccccaagct gctgatctac gccgccagca gcctgcagag cggcgccccc    180

agccgggtga gcggcagcgg cttcggccgg gacttcagcc tgaccatcag cggcctgcag    240

gccgaggact tcggcgccta cttctgccag cagagctaca gcgcccccta caccttcggc    300

cagggcacca aggtggagat caagcggacc                                     330


<210>  12
<211>  110
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.12

<400>  12

Asp Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile 
1               5                   10                  15      


Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ser Ile Asn Lys 
            20                  25                  30          


Tyr Val Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Ala Pro Ser Arg Val Ser 
    50                  55                  60                  


Gly Ser Gly Phe Gly Arg Asp Phe Ser Leu Thr Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ala Glu Asp Phe Gly Ala Tyr Phe Cys Gln Gln Ser Tyr Ser Ala Pro 
                85                  90                  95      


Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 
            100                 105                 110 


<210>  13
<211>  363
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.13

<400>  13
caggtacagc tgcaggagtc aggcccagga ctggtgaagc cttcggagac cctgtccctc     60

acctgcactg tctctggtgg ctccatcagc agaagaagtt actactgggg ctggatccgc    120

cagtccccag ggaaggggct ggagtggagt ggaagtatcc attatagcgg gagcacctac    180

tacaacccgt ccctcaagag tcgagtcacc atatctgtag acacgtccaa gaaccagttc    240

tccctgaaac tgagctctgt taccgccgca gacacggctg tctattactg tgcgagatca    300

cgttggggca gcagctgggt atttgactac tggggccagg gcacactggt caccgtctct    360

tcg                                                                  363


<210>  14
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.13

<400>  14

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Arg 
            20                  25                  30          


Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ser Gly Ser Ile His Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Ser Arg Trp Gly Ser Ser Trp Val Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  15
<211>  330
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13

<400>  15
cagagcgtgc tgacccagcc gccgagcgcg agcggcaccc cgggccagcg cgtgaccatt     60

agctgcagcg gcagcagcag caacattggc agcaactatg tgtattggta tcagcagccg    120

ccgggcaccg cgccgaaact gctgatttat cgcaacaacc agcgcccgag cggcgtgccg    180

gatcgcttta gcggcagcaa aagcggcacc agcgcgagcc tggcgattag cggcctgcgc    240

agcgaagatg aagcggatta ttattgcgcg gcgtgggatg atagcctgag cggctatgtg    300

tttggcaccg gcaccaaagt gaccgtgctg                                     330


<210>  16
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13

<400>  16

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 
            20                  25                  30          


Tyr Val Tyr Trp Tyr Gln Gln Pro Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 
                85                  90                  95      


Ser Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly 
            100                 105                 110     


<210>  17
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.10 CDR1

<400>  17

Ser Tyr Gly Ile His 
1               5   


<210>  18
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.10 CDR2

<400>  18

Val Ile Trp Phe Asp Gly Thr Lys Lys Tyr Tyr Thr Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  19
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.10 CDR3

<400>  19

Asp Arg Gly Ile Gly Ala Arg Arg Gly Pro Tyr Tyr Met Asp Val 
1               5                   10                  15  


<210>  20
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.11 and 
       NI-101.12F6A CDR1

<400>  20

Ser Tyr Gly Met His 
1               5   


<210>  21
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.11 and 
       NI-101.12F6A CDR2

<400>  21

Val Ile Trp Phe Asp Gly Thr Lys Lys Tyr Tyr Thr Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  22
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.11 and 
       NI-101.12F6A CDR3

<400>  22

Asp Arg Gly Ile Gly Ala Arg Arg Gly Pro Tyr Tyr Met Asp Val 
1               5                   10                  15  


<210>  23
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.10, NI-101.11, and
       NI-101.12F6A CDR1

<400>  23

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 
1               5                   10      


<210>  24
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.10, NI-101.11, and
       NI-101.12F6A CDR2

<400>  24

Ala Ala Ser Ser Leu Gln Ser 
1               5           


<210>  25
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.10, NI-101.11, and
       NI-101.12F6A CDR3

<400>  25

Gln Gln Ser Tyr Ser Thr Pro Leu Thr 
1               5                   


<210>  26
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.12 CDR1

<400>  26

Ser Gly Ser Ile Cys 
1               5   


<210>  27
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.12 CDR2

<400>  27

Trp Ile Gly Tyr Phe Cys Tyr Ser Gly Ala Thr Phe Tyr Thr Pro Ser 
1               5                   10                  15      


Leu Arg Gly 
            


<210>  28
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.12 CDR3

<400>  28

Arg Ala Gly Glu Asn Ser Gly Gly Ile Glu Pro Tyr Tyr Gly Met Asp 
1               5                   10                  15      


Val 
    


<210>  29
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.12 CDR1

<400>  29

Arg Ala Ser Glu Ser Ile Asn Lys Tyr Val Asn 
1               5                   10      


<210>  30
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.12 CDR2

<400>  30

Ala Ala Ser Ser Leu Gln Ser 
1               5           


<210>  31
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.12 CDR3

<400>  31

Gln Gln Ser Tyr Ser Ala Pro Tyr Thr 
1               5                   


<210>  32
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.13, NI-101.13A, 
       and NI-101.13B CDR1

<400>  32

Arg Arg Ser Tyr Tyr Trp Gly 
1               5           


<210>  33
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.13, NI-101.13A, 
       and NI-101.13B CDR2

<400>  33

Ser Ile His Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  34
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.13, NI-101.13A, 
       and NI-101.13B CDR3

<400>  34

Ser Arg Trp Gly Ser Ser Trp Val Phe Asp Tyr 
1               5                   10      


<210>  35
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13 CDR1

<400>  35

Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 
1               5                   10              


<210>  36
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13 CDR2

<400>  36

Arg Asn Asn Gln Arg Pro Ser 
1               5           


<210>  37
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13 CDR3

<400>  37

Ala Ala Trp Asp Asp Ser Leu Ser Gly Tyr Val 
1               5                   10      


<210>  38
<211>  372
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.12F 6A

<400>  38
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60

tcctgtgcag cgtctggatt cgccttcagt agctatggca tgcactgggt ccgccaggct    120

ccaggcaagg ggctggagtg ggtggcagtt atatggtttg atggaactaa aaaatactat    180

acagactccg tgaagggcag attcaccatc tccagagaca attccaagaa cacactgtat    240

ctgcaaatga acaccctgag agccgaggac acggctgtgt attactgtgc gagagatagg    300

ggtataggag ctcggcgggg gccgtactac atggacgtct ggggcaaagg gaccacggtc    360

accgtctcct ca                                                        372


<210>  39
<211>  124
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.12F 6A

<400>  39

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Phe Asp Gly Thr Lys Lys Tyr Tyr Thr Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Gly Ile Gly Ala Arg Arg Gly Pro Tyr Tyr Met Asp 
            100                 105                 110         


Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 


<210>  40
<211>  324
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.12F 6A

<400>  40
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc     60

atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca acagaaacca    120

gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca    180

aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct    240

gaagattttg caacttatta ctgtcagcag agttacagta cccctctcac tttcggcgga    300

gggaccaagg tggagatcaa acgt                                           324


<210>  41
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.12F 6A

<400>  41

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


<210>  42
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.13A

<400>  42

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Arg 
            20                  25                  30          


Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ser Gly Ser Ile His Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Ser Arg Trp Gly Ser Ser Trp Val Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  43
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.13B

<400>  43

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Arg 
            20                  25                  30          


Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ser Gly Ser Ile His Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Ser Arg Trp Gly Ser Ser Trp Val Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  44
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13A

<400>  44

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Arg Thr 
                85                  90                  95      


Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105         


<210>  45
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13B

<400>  45

Asp Ile Gln Leu Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105             


<210>  46
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13A CDR1

<400>  46

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 
1               5                   10      


<210>  47
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13A CDR2

<400>  47

Ala Ala Ser Ser Leu Gln Ser 
1               5           


<210>  48
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13A CDR3

<400>  48

Gln Gln Ser Tyr Ser Thr Arg Thr 
1               5               


<210>  49
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13B CDR1

<400>  49

Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala 
1               5                   10      


<210>  50
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13B CDR2

<400>  50

Lys Ala Ser Ser Leu Glu Ser 
1               5           


<210>  51
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13B CDR3

<400>  51

Gln Gln Tyr Asn Ser Tyr Ser Arg Thr 
1               5                   


<210>  52
<211>  363
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.13A

<400>  52
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc     60

acctgcactg tctctggtgg ctccatcagc agaagaagtt actactgggg ctggatccgc    120

cagtccccag ggaaggggct ggagtggagt ggaagtatcc attatagcgg gagcacctac    180

tacaacccgt ccctcaagag tcgagtcacc atatctgtag acacgtccaa gaaccagttc    240

tccctgaaac tgagctctgt taccgccgca gacacggctg tctattactg tgcgagatca    300

cgttggggca gcagctgggt atttgactac tggggccagg gaaccctggt caccgtctcc    360

tcg                                                                  363


<210>  53
<211>  363
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable heavy chain antibody NI-101.13B

<400>  53
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc     60

acctgcactg tctctggtgg ctccatcagc agaagaagtt actactgggg ctggatccgc    120

cagtccccag ggaaggggct ggagtggagt ggaagtatcc attatagcgg gagcacctac    180

tacaacccgt ccctcaagag tcgagtcacc atatctgtag acacgtccaa gaaccagttc    240

tccctgaaac tgagctctgt taccgccgca gacacggctg tctattactg tgcgagatca    300

cgttggggca gcagctgggt atttgactac tggggccagg gaaccctggt caccgtctcc    360

tcg                                                                  363


<210>  54
<211>  324
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic variable light chain antibody NI-101.13A

<400>  54
gacatccagt tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc     60

atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca gcagaaacca    120

gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca    180

aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct    240

gaagattttg caacttacta ctgtcaacag agttacagta ccagaacgtt cggccaaggg    300

accaaggtgg agatcaaacg tacg                                           324


